The current standard therapeutic regimen for the people with locally-advanced non-small cell lung cancer (NSCLC) without a mutation is platinumbased double-agent chemotherapy. Their effectiveness against NSCL and systemic toxicity must be known in advance to utilize these drugs effectively. Many biomarkers have emerged as prognostic and predictive markers for NSCLC. Among them, the common biomarkers are the epidermal growth factor receptor (EGFR), 5 endonuclease enzyme of nucleotide excision repair (ERCC1), Kirsten sarcoma virus, which is a proto-oncogene (K-ras), and regulator subunit of ribonucleotide reductase. Besides, there is huge evidence suggesting that there might be a prognosis between NSCLC and BRCA1, XOR. 1-3 Many studies on the prognostic and predictive values of BRCA1 and XOR in patients with NSCLC have been carried out previously. However, very few of them have addressed the effect of neoadjuvant chemotherapy on pathological tissue markers. 4-8 This study aimed to determine the role of XOR activity in NSCLC and show the association of

No abstract